

Recommended Guidelines for Validation, Quality Control, and Reporting of *TP53* Variants in Clinical Practice

Bernard Leroy¹, Mandy L. Ballinger², Fanny Baran-Marszak³, Gareth L. Bond⁴, Antony Braithwaite^{5,6}, Nicole Concin⁷, Lawrence A. Donehower⁸, Wafik S. El-Deiry⁹, Pierre Fenaux¹⁰, Gianluca Gaidano¹¹, Anita Langerød¹², Eva Hellstrom-Lindberg¹³, Richard Iggo¹⁴, Jacqueline Lehmann-Che¹⁵, Phuong L. Mai¹⁶, David Malkin¹⁷, Ute M. Moll¹⁸, Jeffrey N. Myers¹⁹, Kim E. Nichols²⁰, Sarka Pospisilova²¹, Patricia Ashton-Prolla²², Davide Rossi¹¹, Sharon A. Savage²³, Louise C. Strong²⁴, Patricia N. Tonin²⁵, Robert Zeillinger²⁶, Thorsten Zenz²⁷, Joseph F. Fraumeni Jr²⁸, Peter E.M. Taschner²⁹, Pierre Hainaut³⁰, and Thierry Soussi^{1,31,32}

Abstract

Accurate assessment of *TP53* gene status in sporadic tumors and in the germline of individuals at high risk of cancer due to Li–Fraumeni Syndrome (LFS) has important clinical implications for diagnosis, surveillance, and therapy. Genomic data from more than 20,000 cancer genomes provide a wealth of information on cancer gene alterations and have confirmed *TP53* as the most commonly mutated gene in human cancer. Analysis of a database of 70,000 *TP53* variants reveals that the two newly discovered exons of the gene, exons 9 β and 9 γ , generated by alternative splicing, are

the targets of inactivating mutation events in breast, liver, and head and neck tumors. Furthermore, germline rearrangements in intron 1 of *TP53* are associated with LFS and are frequently observed in sporadic osteosarcoma. In this context of constantly growing genomic data, we discuss how screening strategies must be improved when assessing *TP53* status in clinical samples. Finally, we discuss how *TP53* alterations should be described by using accurate nomenclature to avoid confusion in scientific and clinical reports.

Cancer Res; 77(6); 1–11. ©2017 AACR.

¹Sorbonne Université, UPMC Univ Paris 06, Paris, France. ²Cancer Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia. ³Hôpital Avicenne, Assistance Publique–Hôpitaux De Paris, Bobigny, Service D'Hématologie Biologique, France. ⁴Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom. ⁵Dept of Pathology, School of Medicine, University of Otago, Dunedin, New Zealand. ⁶Children's Medical Research Institute, University of Sydney, Westmead NSW, Australia. ⁷Department of Gynecology and Obstetrics, Innsbruck Medical University, Innsbruck, Austria. ⁸Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas. ⁹Department of Hematology/Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. ¹⁰Service d'hématologie séniors, Hôpital St Louis/Université Paris 7, 1 avenue Claude Vellefaux, Paris, France. ¹¹Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy. ¹²Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. ¹³Karolinska Institute, Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska University Hospital, Stockholm, Sweden. ¹⁴Bergonié Cancer Institute University of Bordeaux 229 cours de l'Argonne 33076 Bordeaux, France. ¹⁵Molecular Oncology Unit, Hospital Saint Louis, Paris, France. ¹⁶Cancer Genetics Program, Magee Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. ¹⁷Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. ¹⁸Department of Pathology, Stony Brook University, Stony Brook, New York. ¹⁹The University of Texas MD Anderson Cancer Center, Houston, Texas. ²⁰Department of Oncology, Division of Cancer Predisposition, St. Jude Children's Research Hospital, Memphis, Tennessee. ²¹Masaryk University, CEITEC – Molecular Medicine and University Hospital Brno, Department of Internal Medicine – Hematology and Oncology, Brno, Czech

Republic. ²²Universidade Federal do Rio Grande do Sul (UFRGS) e Serviço de Genética Médica-HCPA, Rua Ramiro Barcelos, Porto Alegre, Brasil. ²³Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. ²⁴The University of Texas MD Anderson Cancer Center, Houston, Texas. ²⁵Departments of Medicine and Human Genetics, McGill University and Cancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. ²⁶Molecular Oncology Group, Department of Obstetrics and Gynaecology, Medical University of Vienna, Vienna, Austria. ²⁷University of Heidelberg, Department of Medicine V, Heidelberg, Germany; Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center (dkfz), Heidelberg, Germany. ²⁸Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. ²⁹Generate Centre of Expertise Genomics and University of Applied Sciences Leiden, Leiden, the Netherlands. ³⁰Institut Albert Bonniot, Inserm 823, Université Grenoble Alpes, Rond Point de la Chantourne, La Tronche, France. ³¹Department of Oncology-Pathology, Karolinska Institutet, Cancer Center Karolinska, Stockholm, Sweden. ³²INSERM, U1138, Centre de Recherche des Cordeliers, Paris, France.

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

Corresponding Author: Thierry Soussi, Karolinska Institutet, Cancer Centrum Karolinska, Stockholm 17176, Sweden and Sorbonne Université, UPMC Univ Paris 06, Paris, France. Phone: 46-8-5177-733. E-mail: thierry.soussi@ki.se or thierry.soussi@upmc.fr

doi: 10.1158/0008-5472.CAN-16-2179

©2017 American Association for Cancer Research.

Introduction

A major goal of cancer research is the identification of tumor-specific vulnerabilities that can be exploited to tailor treatment to the unique genetic and epigenetic tumor profile of individual patients (1). This can be achieved as a result of the enormous progress in cancer genomics and the increasingly detailed knowledge of the genetic landscape of the most common tumor types. Single-nucleotide variants (SNV) as well as small insertions and deletions (indels) targeting cancer genes are among the most common deleterious genetic events that are scattered throughout the entire genome of the tumor (2). In this article, the term "variant" will be used to describe genetic changes (see Box A for more information on terminology).

A unique three-phase pattern of variant description is observed following the discovery of a novel cancer gene:

Box A: How to avoid confusion: Definitions of genetic variation terminology according to the Human Genome Variation Society

Recommended standard terms:

1 *Variant*: every permanent *genetic change*.

Connotation: Neutral. Recommended by ACMG and AMP.

Avoid using *Mutation* to indicate the *variant* itself, because of its negative connotation due to frequent use as *disease-causing variant* instead of the broader concept *variant*. *Mutation* can be used to describe the **process** or **event** generating genetic variation.

Avoid using the term *Polymorphism*. In its original meaning: *a variant with a frequency of 1% or higher in the population*. Due to its frequency, considered to be *nondisease-causing*.

Avoid using the term *Single Nucleotide Polymorphism (SNP)*: *variant present in dbSNP*. dbSNP now contains other types of short sequence variants. In addition, rare variants causing hereditary disease and somatic variants are accepted. In conclusion: no longer synonymous with *nondisease-causing*.

2 *Affects function*: HGVS recommended modifier alternative for the term *Pathogenic* used to indicate a *disease-causing* effect. The term *pathogenic* is inappropriate for use with traits and creates confusion when used without mentioning *specific context (in combination with a similar variant on the same allele)* or *conditions (when inherited from the father, imprinted)* necessary to observe the functional effect causing disease. Germline variants in tumor suppressor genes can only be considered as having functional effects when somatic second hits inactivate the second allele in tumors.

HGVS recommended five-tier variant classification system: *affects function, probably affects function, unknown, probably does not affect function (or probably no functional effect), or does not affect function (no functional effect)*.

The ACMG and AMP guidelines still include the five-tier variant classification system relevant to Mendelian disorders, *pathogenic, likely pathogenic, uncertain significance, likely benign, or benign*, but recommend providing the condition and inheritance pattern to clarify the context in reports.




Figure 1.

Cancer gene variant discovery and validation: pathway to clinical practice. The discovery and validation of cancer gene variants follow several phases that resemble those used for other cancer biomarkers. During the discovery phase, publications precisely describe novel variants and discuss their potential pathogenicity in relation to the disease. A burst of studies then leads to the identification of novel and generally diverse variants. This phase is commonly associated with parallel reports on the mutation rate and/or clinical novelties, often published in journals with a high impact factor. Transition to the validation phase occurs rapidly when genetic and clinical data start to become redundant. During this phase, sequencing of multiple new clinical specimens mostly reveals variants that have already been described and variant diversity will begin to reach a plateau. The length of this phase is highly dependent on the number of genetic events needed to modify the targeted gene. For oncogenes that require specific events to change their function, this number tends to be limited, because most of them will be missense variants targeting a critical functional region. In contrast, tumor suppressor genes may harbor a large number of genetic events, including nonsense variants, splice variants, as well as indels of varying size scattered throughout the gene. This validation phase is vital, as it adds nuance and validates data from the discovery phase in a wide variety of clinical and/or geographical settings. Consequently, variants are either described in supplementary materials or quoted as unpublished data, leading to a decrease in reported variants. Except for a few very specific cases, the validation phase is accompanied by a decrease in the impact factor of the publishing journals. This decrease in descriptions of variants does not reflect their frequency in the disease or the incidence of their analysis, but rather a lack of interest and lack of novelty, introducing a bias against their publication. If the variants have no clinical significance, the number of studies will decrease rapidly, and then stop. It has also been observed that the validation phase is associated with an increase in inconsistent studies. An extensive analysis of the various flaws associated with the publication of variants was provided by Kern and Winter in their 2006 review (84). Finally, transition to the clinical practice phase then begins for variants of clinical interest. However, publications fall off, as service laboratories do not consider reporting them in the literature to be an essential part of their work. Descriptions of novel variants then become scarce.

discovery, validation, and clinical practice (Fig. 1; ref. 3). The duration of these phases, individually and globally, depends on the scientific "popularity" of the gene, the type of alteration and its clinical relevance (Fig. 1). For several genes, such as *BRAF*, for which the first variants were described in 2002, the three-phase workflow was rapidly completed due to the very limited diversity of the variants. The *BRAF* variant NM_004333.4:c.1799T>A (p.Val600Glu) is virtually the only

deleterious variant reported in a wide variety of cancers, including melanoma, papillary thyroid cancer, colorectal carcinoma, glioma, and other cancers, and successful targeted therapy has already been developed (4). The three-phase workflow is also well illustrated by the analysis of the *TP53* suppressor gene. The discovery phase began in 1989 with the first description of *TP53* variants in lung and colorectal cancers (5, 6). Over the following years, there was a steady increase in the number of publications describing novel *TP53* alterations in most cancer types, culminating in over 10,000 variants (encompassing about 2,500 distinct mutational events) reported in 300 publications by 2001 (7, 8). More than 85% of the different missense *TP53* variants reported in the various *TP53* databases were identified during the discovery phase. The decline in the number of published *TP53* variants began in 2002, corresponding to the beginning of the second, validation phase. The latest issue of the *TP53* variant database was released in 2015 and contains a total of 60,000 variants, encompassing 1,700 different missense and nonsense variants (9). The number of novel single-base variants has not increased significantly for several years now, indicating that a saturation plateau has been reached with the discovery of all potential deleterious *TP53* variants.

TP53 mutation analysis has now reached the third phase with the development of clinical guidelines for *TP53* mutation testing in various settings. Germline *TP53* variants have emerged as a significant cause of genetic predisposition to cancer associated with LFS (10). The most recent version of the National Comprehensive Cancer Network (NCCN) guidelines recommends *TP53* mutation testing in individuals with onset of breast cancer before 31 years of age, either concurrently with *BRCA1/2* testing or as a follow-up test after negative *BRCA1/2* testing (NCCN Guidelines Version 1.2017, http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf). Somatic *TP53* mutation analysis is now widely used in clinical trials involving patient stratification based on *TP53* status and in trials of novel drugs targeting either wild-type or mutant *TP53* in order to activate a *TP53* antitumor response. *TP53* mutation screening is therefore rapidly becoming an integral part of many therapeutic or prevention strategies in clinical practice.

The *TP53* Network

The transcription factor, p53 protein, is at the center of a network that integrates and transmits multiple signals, generated during various stress events to ensure cell and tissue homeostasis (11–13). These pathways include two other members of the p53 family, *TP63* and *TP73* (14, 15), as well as two negative regulators, *MDM2* and *MDM4* (previously called *MDMX*; ref. 16). p53 also has transcription-independent functions via a direct interaction with pro- and antiapoptotic factors in mitochondria, thereby regulating apoptosis (17).

Under normal conditions, p53 protein is maintained at low levels as a result of rapid turnover mediated by *Mdm2*, its main negative regulator. In response to various forms of stress, p53 becomes activated and elicits a variety of activities including cell growth arrest, apoptosis, or senescence to prevent the propagation of aberrant cells. Although these three cellular responses were originally associated with the tumor suppressor activity of *TP53*, their importance has recently been challenged in several mouse models (18).

Recent evidence has also linked *TP53* function to regulation of metabolism and the redox balance to maintain intracellular homeostasis (19). Whether or not these functions are associated with the tumor suppressor effect of *TP53* remains to be elucidated.

A discussion of all aspects of the various signaling pathways regulated by *TP53* is beyond the scope of this article and recent reviews on this subject are available (12, 20, 21).

Heterogeneity of *TP53* Variants

Among the 14 million new cases of cancer diagnosed in 2012, 7 to 8 million (50 to 60%) tumors harbored a somatic *TP53* variant (<http://globocan.iarc.fr>). With a few exceptions, such as testicular cancer, neuroblastoma, or mesothelioma, *TP53* variants can be detected in all types of cancer with a high degree of heterogeneity (ranging from 10% to 90%), making *TP53* the most frequently mutated gene in human cancer (2, 22). Apart from variants, *TP53* function can also be inactivated via other mechanisms such as amplification of its negative regulators *MDM2* and *MDM4* or by binding to viral oncoproteins such as E6, expressed by human papillomavirus (23, 24). In acute myeloid leukemia, hyperactivity of histone deacetylase HDAC8 prevents posttranslational acetylation-mediated activation of the p53 protein, which is essential for its tumor suppressor function (25).

Among the 60,000 tumors that harbor *TP53* modifications described to date, missense alterations in the coding region of the full-length protein are the most common alterations. Approximately 1,500 different missense *TP53* variants have been identified, ranging from several hot spots at positions 175, 248, or 273, reported several thousand times in many different tumors, to infrequent variants detected at very low frequencies (9). On the other hand, more than 4,000 *TP53* variants are frameshift events leading to incorrect protein synthesis. This observation raises two important issues that have not been fully resolved. The first issue concerns the pathogenicity of all of these variants. Although there is no longer any doubt about the loss of function of the various hot spot variants, the loss of function of less frequent variants, particularly those that have been described at very low frequencies, remains unclear (26). This is a key issue for genetic counseling, as the use of NGS has led to the discovery of very rare novel germline *TP53* variants of unknown significance (VUS) in the normal population (27). Multiple methodologies have been developed to assess the functional effect of *TP53* variants, but their specificities and sensitivities remain low for uncommon variants (28–30).

The second issue concerns the heterogeneity of *TP53* variants. Missense mutant proteins exhibit severely impaired transcriptional activity as well as a gain of oncogenic activities that promote tumorigenesis, leading to the notion that tumors are addicted to mutant p53 (22, 31, 32). Furthermore, a wealth of *in vitro* data as well as data from animal models indicate that the oncogenic activities of *TP53* variants are heterogeneous and can vary according to the tissue type and the genetic background of the cells (33–36). In breast carcinoma, the spectrum of *TP53* variants is subtype specific, each one with a different prognostic relevance (37). Classifying *TP53* status as either "wild-type" or "mutant" is therefore an oversimplification, as *TP53*-null tumors due to loss of p53 expression have a different phenotype compared to tumors overexpressing an oncogenic *TP53* variant.

Clinical Relevance of *TP53* Mutation

Somatic *TP53* mutation in human tumors

The predictive and prognostic value of *TP53* status in various types of cancer has been the subject of several thousand studies with conflicting findings and limited clinical application, and a review of this literature is beyond the scope of this article (38–40). These discordant results are due to multiple causes, such as the methodology and strategy used to assess *TP53* status, the heterogeneity of tumor types, the genetic background of the tumor, and the large number of different *TP53* variants.

To circumvent some of these problems, *TP53* variants have been tentatively divided into different categories according to their localization on the protein, the type of variant (missense versus indel) or the evolutionary conservation of the mutated residue. Although some of these classifications have improved the clinical value of *TP53* status for head and neck cancer (30), breast carcinoma (41), or diffuse large B-cell lymphoma (42), no clear rationale to definitively score *TP53* variants has yet been defined.

One of the best examples of the clinical value of *TP53* status is chronic lymphocytic leukemia. Although the frequency of *TP53* variants is very low in asymptomatic patients, the presence of *TP53* variants is usually associated with poor prognosis characterized by advanced clinical stage, rapid disease progression, chemoresistance, and shorter overall survival (43). The recent CLL8 trial identified *TP53* variants as one of the strongest prognostic markers in patients receiving standard-of-care first-line therapy (44). An European consortium (European Research Initiative on CLL, ERIC) has developed and standardized the *TP53* mutation analysis in CLL to allow better patient stratification (45).

The development of liquid biopsies and analysis of circulating cell-free tumor DNA (ctDNA) as a surrogate for tumor genotyping has raised renewed interest in *TP53* variants, as the high gene mutation rate makes *TP53* an attractive biomarker (46). ctDNA analysis during therapy can provide early information about treatment resistance related to the emergence of *TP53* variants in response to the selective pressure of therapies. In many tumor types, such as lung, gastric, high-grade serous ovarian, or breast carcinoma, *TP53* variants are an early event that can be detected in ctDNA from patients with early-stage disease (47, 48). The possible role of detection of *TP53* variants in ctDNA from individuals at high risk of cancer, allowing early clinical diagnosis and resulting in a higher cure rate, constitutes an exciting challenge for the future.

Because of the extremely high frequency of missense variants, the oncogenic gain of function of many variants and the fact that cancer cells overexpress the mutant protein, *TP53* is a promising target for the development of therapies designed to induce inhibition or restoration of p53 function by small molecules (49). This prospect is supported by recent studies showing that reconstitution of p53 activity leads to the suppression of established tumors in mouse models (50, 51). Molecules targeting mutant p53 have been developed and are currently at the stage of clinical trials (52). Components of the various pathways leading to accumulation of mutant p53, such as hsp90 (53), or gain of function, such as TP73, can also be targeted (54). More than 150 clinical trials related to *TP53* pathways are currently under way, including the use of novel molecules that specifically target mutant p53 (55).

Germline *TP53* variants in hereditary cancer predisposition syndromes

Germline *TP53* variants were first identified in individuals from families with LFS (56). LFS is a rare autosomal dominant syndrome, in which patients are predisposed to a wide variety of cancer types, with a young age at onset of malignancies, and the potential for multiple primary cancer sites during the affected individual's lifetime (57). A Li–Fraumeni-like (LFL) syndrome with less stringent criteria than LFS was subsequently described. The frequency of *TP53* variants in LFS and LFL is 70% and 20% to 40%, respectively. LFS and LFL present a similar spectrum of germline and somatic *TP53* variants with missense and indel variants scattered throughout the gene. The frequency of *de novo* *TP53* mutation (creating variants in the germ cells of one of the parents or in the fertilized egg) has been estimated to be as high as 30%, which is very high compared with the frequency of other tumor suppressor genes such as *BRCA1/2* (less than 5%; ref. 58). Identification of *TP53* germline variants in LFS and LFL could potentially be beneficial for individual patients by allowing initiation of surveillance, early cancer detection, and/or prevention (59).

A specific pathogenic germline variant arising from a founder event (c.1010G>A, p.(Arg337His)) has been identified in Brazilian children with adrenal cortical carcinomas (ACC; ref. 60). The prevalence of this variant is particularly high in Southern Brazil, where it can be as high as 0.3% in the general population (61) and is also common in patients with LFS and LFL from this geographical region (62).

Recent studies have detected germline *TP53* variants in various cohorts of *BRCA1/2*-negative patients with early onset of breast cancer, indicating that the *TP53* gene should be added to the cancer gene panel used for screening in these patients (63–66).

Assessing *TP53* Status in Human Cancer

TP53 mutation analysis has now reached the clinical practice phase, as cancer patients are likely to benefit from this information. Somatic *TP53* variants were initially reported to cluster within DNA sequences encompassing exons 5 through 8, encoding the core DNA-binding domain of the protein (6, 67). The majority of subsequent studies therefore exclusively focused on these regions, introducing a major bias with underrepresentation of variants that may occur in other regions of the gene. Over the last decade, most sequencing centers encompass the entire coding region of the gene, and this expanded coverage, together with the recent use of next-generation sequencing (NGS) that covers all *TP53* exons, has revealed that up to 10% of *TP53* variants are localized in exons 2 to 4 and exons 9 to 11 (9). Of note, the spectrum of these variants differs from that of variants occurring in exons 5 to 8, as they mostly consist of indels that usually lead to a *TP53*-null phenotype (9). The discovery and validation phases have clearly demonstrated the pathogenicity of these variants as well as their clinical utility; screening exons 2 to 11 is now highly recommended (Fig. 2).

For a long time, the *TP53* gene was considered to be expressed as a single protein of uniform size (mRNA derived from exons 2–11, encoding 393 amino acids). However, the more complex architecture and expression pattern of the *TP53* gene has only been recognized in recent years (Fig. 3 and Supplementary Fig. S1). *TP53* mobilizes various mechanisms to transcribe at least eight different mRNA isoforms, which are generated by alternative splicing or alternative promoter usage (68, 69). Collectively, these




Figure 2.

Assessment of *TP53* status. Sequencing of the classical exons 2 to 11 (including splice junctions) is now mandatory, as discovery and validation phases have both demonstrated that variants are scattered throughout these exons. A few variants have been discovered in exons 9 β and 9 γ , but their functional effect is currently unknown and more data are needed to assess their recurrence (Fig. 3 and Table 1). Additional studies will need to be performed to ensure that these variants are true driver variants and not simply rare or passenger variants. The region of intron 4 contains the second internal promoter P2 that leads to the expression of 9 additional protein isoforms as well as a *TP53* response element (TP53RE). Whether or not variants in this region can alter *TP53* status and impair its tumor suppressor function remains unknown. Recent studies have shown that a rare variant in dbSNP, rs78378222, localized in the Poly A signal of the *TP53* gene, leads to impaired 3'-end processing of mRNA and confers susceptibility to various types of cancer (blue triangle; ref. 85). The validation phase for these various events could be performed *in silico* using data obtained from whole-genome sequencing of tumors, as these regions were most probably sequenced, but discarded by the various filtering processes used in the analytical pipelines. The frequency of *TP53* variants in each coding exon is shown above each exon. Green and red triangles correspond to the start and STOP codons, respectively.


mRNAs have the potential to give rise to up to 12 different proteins, although the exact expression level, tissue distribution, and biological function of each of these protein variants are poorly understood. This complex expression pattern implies that sequences located in *TP53* introns and involved in the production of alternative forms of the protein may have a critical impact on overall biological functions of p53 and may therefore be important target regions for somatic or germline variants. Mouse models have shown that constitutive expression of a short p53 isoform lacking the transactivation domain ($\Delta 122$ p53) leads to chronic inflammation and a different and more aggressive tumor spectrum compared with *TP53*-null mice, suggesting that this isoform could act as a dominant oncogene (70).

Intron 9 of *TP53* is a typical example of this type of situation, as it has now been clearly established that intron 9 contains two novel alternative exons, each one encoding a different carboxy-terminus for the p53 protein (Fig. 2; ref. 71). The biological functions of these novel p53 protein isoforms, p53 β and p53 γ , have not yet been elucidated. Both proteins lack part of the oligomerization domain and have different transcriptional activities compared with full-length p53 (72).

Because of the bias toward screening for somatic variants exclusively in exons 5 to 8, these alternative exons have been excluded from most studies that used Sanger sequencing to assess variants. The increasing use of NGS strategies that address a broader range of sequences within the *TP53* locus demonstrates that significant variants may occur within these alternative exons. The latest version of the UMD *TP53* database containing 78,000

TP53 variants derived from 4,200 curated and annotated publications including recent whole-genome sequencing studies was released in December 2016. Analysis of this database identified several somatic nonsynonymous variants in the coding region of exon 9 β and five nonsynonymous variants in the coding region of exon 9 γ (Fig. 3 and Table 1). Furthermore, two variants in the untranslated region of exon 9 β and four variants in a splice signal common to both alternative mRNA isoforms were also identified (Fig. 3 and Table 1). Analysis of the latest issue of dbSNP (build 148, https://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi) also showed that numerous synonymous and nonsynonymous germline variants are localized in introns 9 β and γ (Table 1). The clinical significance of these variants is unknown at the present time, but their discovery warrants further analysis to validate whether or not screening of this region could be important to determine *TP53* status.

Another example of the importance of including *TP53* intronic sequences in mutation screening strategies is the identification of a hotspot region for rearrangements occurring in intron 1. More than 20 years ago, recurrent rearrangements in *TP53* intron 1 (~10 kb) were identified by Southern blot, but at the time this information was not included in guidelines for mutation screening (73, 74). A recent study of intron 1 rearrangements found cosegregation with cancer risk in four generations of a family with LFS features, suggesting this genetic alteration may predispose to a wide range of cancers (75). However, intron 1 rearrangements have been observed in only one type of sporadic cancer, osteosarcoma, where they occur in about 50% of cases (75, 76). Of

**Figure 3.**

TP53 variants detected in exon 9 β and exon 9 γ . Alternative splicing events in *TP53* intron 9 lead to the expression of β and γ isoforms. Exons 9 β and 9 γ have different splice acceptor sites, but share the same donor site (blue AG and GT sequence, respectively). Due to the marked overlap between the two exons, it is possible that substitutions localized in the translated region of exon 9 γ impair exon 9 β splicing. The main splicing event occurs between exon 9 and 10. Somatic variants detected in human cancer are shown in red, whereas germline variants from dbSNP are shown in green. See Table 1 for more information. The intron 9 splice donor site contains three single-nucleotide substitutions and one insertion in three different tumors. The NC_000017.10:g.7576525A>C substitutions modify *TP53* splicing by leading to an unbalanced ratio of the various *TP53* mRNAs and a greater abundance of β isoforms (86). Similarly, the three-nucleotide insertion detected in a lymphoma (NC_000017.10:g.7576522_7576523insCTT) probably has a deleterious effect on splicing. The substitution at the stop codon (NM_000546.5:c.993+314T>C) is predicted to add 17 novel amino acid residues to the 10 residues encoded by exon 9 β . All these variations are concentrated within a narrow 150-bp region of intron 9, which is 2,800 nucleotides long. A total of 22 germline variants, shown in green, have been identified by mining the most recent versions of the dbSNP (https://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi) and the 1000-Genome databases (<http://browser.1000genomes.org/index.html>). Several of these variants are identical to those found as somatic events in human tumors. It is not known whether these variants are neutral or associated with an increased risk of cancer. Overall, these data indicate that *TP53* exon 9 β and exon 9 γ are targeted by substitutions in human cancer and contain numerous germline variants. Due to the importance of *TP53* status in the evaluation of patients with multiple primary cancers or a strong family history of cancer, analysis of exons 9 β and 9 γ is now warranted to more clearly determine the clinical significance of germline variants in this region.

note, osteosarcoma has long been considered to be a type of cancer in which missense *TP53* variants were relatively rare, and it has been proposed that amplification of *MDM2*, rather than *TP53* variants, was a key mechanism for inactivation of the p53 protein in these cancers (77). The detection of intronic rearrangements in a large subset of human osteosarcoma suggests that this cancer should also be considered to have a high rate of somatic *TP53* aberrations. In most cases analyzed to date, rearrangements in intron 1 led to balanced translocations involving different chromosomes, apparently without preference for a specific translocation product. The sites of breakpoints for rearrangements in intron 1 currently remain unclear. Ribi and colleagues have documented seven rearrangements that all occurred within a defined region of 1.7 kb (75). In contrast, in another study, Chen and colleagues

(76) identified breakpoints occurring across the entire sequence of intron 1.

Several N-terminally truncated p53 isoforms are encoded by transcripts generated by a promoter localized in intron 4 of the *TP53* gene (Supplementary Fig. S1). It is conceivable that variants localized in this region would impair the synthesis of several p53 isoforms. This question has yet to be resolved, and a discovery phase will be necessary to investigate further.

The Importance of Rigorous Description of Genetic Variants and Their Effects

Most researchers and clinicians like to describe genetic variants in a tangible way in terms of the protein. Amino acid

Table 1. TP53 variants targeting specifically exon 9β and exon 9γ sequences and their splice sites.

Sample ID/ SNP_ID ^a	Origin ^b	Chromosomal reference NC_000017.10 ^c	Main TP53 transcript NM_000546.5 ^d	Exon 9β transcript NM_001126114.2 ^e	Exon 9γ transcript NM_001126113.2 ^f	Exon 9β protein NP_001119586.1 ^g	Exon 9γ protein NP_001119585.1 ^h
V6	Skin SCC	g.7576659A>G	c.993+194A>G	c.994-2A>G	c.994-73A>G	p.(?)	
rs750031971	dbSNP	g.7576655C>T	c.993+198C>T	c.996C>T	c.994-69C>T	p.(D332=)	
rs764851816	dbSNP	g.7576654C>G	c.993+199C>T	c.997C>T	c.994-68C>G	p.Q333E	
rs761303879	dbSNP	g.7576637A>C	c.993+216A>C	c.1014A>C	c.994-51A>C	p.K338N	
12a	Head and neck SCC	g.7576636G>C	c.993+217G>C	c.1015G>C	c.994-50G>C	p.E339Q	
SA500637	HCC	g.7576633A>G	c.993+220A>G	c.1018A>G	c.994-47A>G	p.N340D	
JEN9 (rs3021068)	dbSNP	g.75766301>G	c.993+223T>G	c.1021T>G	c.994-44T>G	p.C341G	
rs3021068	dbSNP	g.7576630T>G	c.993+223T>G	c.1021T>G	c.994-44T>G	p.C341G	
rs3021068	dbSNP	g.7576630T>A	c.993+223T>A	c.1021T>A	c.994-44T>G	p.C341S	
SLN2522	Burkitt lymphoma	g.7576626A>C	c.993+227A>C	c.1025A>C	c.994-40C>C	p.*342Sext17	
Au3	Melanoma	g.7576626A>G	c.993+227A>G	c.1025A>G	c.994-40A>G	p.(*)	
rs764562217	dbSNP	g.7576626A>C	c.993+227A>C	c.1025A>C	c.994-40A>G	p.*342Sext17	
rs761121529	dbSNP	g.7576625A>G	c.993+228A>G	c.1026A>G	c.994-39A>G	p.(*)	
rs17883348	dbSNP	g.7576619G>A	c.993+234G>A	c.*6G>A	c.994-33G>A		
rs76532147	dbSNP	g.7576609G>T	c.993+244G>T	c.*16G>T	c.994-23G>T		
HPB-ALL ¹	T-ALL	g.7576607T>A	c.993+246T>A	c.*18T>A	c.994-21T>A		
RPMI ¹	T-ALL	g.7576607T>A	c.993+246T>A	c.*18T>A	c.994-21T>A		
XHDG17	Gallbladder ca.	g.7576601G>A	c.993+252G>A	c.*24G>A	c.994-15G>A		
SA6251-BRCA-UK	Breast carcinoma	g.7576591G>A	c.993+262G>A	c.*34G>A	c.994-5G>A		
BRCA_UK_1	Breast carcinoma	g.7576591G>A	c.993+262G>A	c.*34G>A	c.994-5G>A		
117	B-Chronic lymphocytic leukemia	g.7576572T>G	c.993+281T>G	c.*53T>G	c.1006T>G	p.L336V	
19	Uterine carcinosarcoma	g.7576572.7576568del	c.993+281.993+285del5	c.*53.57del5	c.1006.1010e15	p.L336Mfs*12	
3129	EsophagealAdc	g.7576570A>C	c.993+283A>C	c.*55A>C	c.1008A>C	p.L336F	
SA529425-LINC-JP	Hepatocellular carcinoma	g.7576570A>C	c.993+283A>C	c.*55A>C	c.1008A>C	p.L336F	
SA529505-LINC-JP	Hepatocellular carcinoma	g.7576570A>C	c.993+283A>C	c.*55A>C	c.1008A>C	p.L336F	
COSM1610827	dbSNP	g.7576570A>C	c.993+283A>C	c.*55A>C	c.1008A>C	p.L336F	
DS-54750	dbSNP	g.7576569C>T	c.993+284C>T	c.*56C>T	c.1009C>T	p.R337*	
15	Colorectal carcinoma	g.7576568G>A	c.993+285G>A	c.*57G>A	c.1010G>A	p.R337Q	
rs771319678	dbSNP	g.7576568G>A	c.993+285G>A	c.*57G>A	c.1010G>A	p.R337P	
rs749361930	dbSNP	g.7576568G>C	c.993+285G>C	c.*57G>C	c.1010G>C	p.W338R	
rs1642789	dbSNP	g.7576563T>C	c.993+290T>C	c.*62T>C	c.1015T>C	p.C339R	
rs1642789	dbSNP	g.7576563T>A	c.993+290T>A	c.*62T>A	c.1015T>A	p.C339S	
DS-53453	Colorectal carcinoma	g.7576558C>T	c.993+295C>T	c.*67C>T	c.1020C>T	p.(Y340=)	
rs770028766	dbSNP	g.7576554C>T	c.993+299C>T	c.*71C>T	c.1024C>T	p.(Y340=)	
rs200274944	dbSNP	g.7576546C>T	c.993+307C>T	c.*79C>T	c.1032C>T	p.(Y340=)	
rs200274944	dbSNP	g.7576546C>G	c.993+307C>G	c.*79C>G	c.1032C>G	p.N344K	
YUMUL	Melanoma	g.7576544C>T	c.993+309C>T	c.*81C>T	c.1034C>T	p.S345L	
SJNBL197 ¹	Neuroblastoma	g.7576544C>T	c.993+309C>T	c.*81C>T	c.1034C>T	p.S345L	
5-VS065-T1	Skin basal cell carcinoma	g.7576544C>T	c.993+309C>T	c.*81C>T	c.1034C>T	p.S345L	
rs758194998	dbSNP	g.7576544C>T	c.993+309C>T	c.*81C>T	c.1034C>T	p.S345L	
WD_06	Skin squamous cell carcinoma	g.7576543G>A	c.993+310G>A	c.*82G>A	c.1035G>A	p.(S345=)	
rs201293647	dbSNP	g.7576543G>T	c.993+310G>T	c.*82G>T	c.1035G>T	p.(S345=)	
rs201293647	dbSNP	g.7576543G>A	c.993+310G>A	c.*82G>A	c.1035G>A	p.(S345=)	
12-RS	Richter syndrome	g.7576542T>G	c.993+311T>G	c.*83T>G	c.1036T>G	p.S346A	
DS-53382	Colorectal carcinoma	g.7576542T>C	c.993+311T>C	c.*83T>C	c.1036T>C	p.S346P	
COSM1731910	dbSNP	g.7576542T>G	c.993+311T>G	c.*83T>G	c.1036T>G	p.S346A	
TGCA-HT-A616	Gioma (low grade)	g.7576541C>G	c.993+312C>G	c.*84C>G	c.1037C>G	p.S346W	
rs756952434	dbSNP	g.7576541C>T	c.993+312C>T	c.*84C>T	c.1037C>T	p.S346L	
rs372821099	dbSNP	g.7576540G>A	c.993+313G>A	c.*85G>A	c.1038G>A	p.(S346=)	
SC_9007-Tumor	Prostate carcinoma	g.7576539T>C	c.993+314T>C	c.*86T>C	c.1039T>C	p.*347Qe:xt67	

(Continued on the following page)

Table 1. TP53 variants targeting specifically exon 9β and exon 9γ sequences and their splice sites. (Cont'd)

Sample ID/ SNP_ID ^a	Origin ^b	Chromosomal reference NC_000017.10 ^c	Main TP53 transcript NM_00546.5 ^e	Exon 9β transcript NM_00126114.2 ^f	Exon 9γ transcript NM_001126113.2 ^f	Exon 9β protein NP_00119586.1 ^g	Exon 9γ protein NP_00119585.1 ^h
CCRF-CEM	T-Acute lymphoblastic leukemia	g.7576533G>A	c.993+320G>A	c.*92G>A	c.*4G>A		
rs730882013	dbSNP	g.7576527_7576512del	c.993+326_993+341del16	c.*98_*100+13del16	C*10_12+13del16		
MEL-Ma-Mel-94	Melanoma	g.7576525T>G	c.993+328T>G	c.*100T>G	c.*12T>G		
83 ^k	Breast carcinoma	g.7576525T>G	c.993+328T>G	c.*100T>G	c.*12T>G		
SA505836-OV-AU	Ovarian carcinoma	g.7576525T>G	c.993+328T>G	c.*100T>G	c.*12T>G		
ATH-2	Splenic marginal zone lymphoma	g.7576522insTCT	c.993+331_993+332insTCT	c.*100+2_*100+3*3insTCT	c.*12+2_*12+3*3insTCT		

Abbreviations: BCC, basal cell carcinoma; HCC, hepatocellular carcinoma; SCC, squamous cell carcinoma; T-ALL, T-cell acute lymphoblastic leukemia.

^aSample identifier used in the original publication or in dbSNP.

^bOrigin: somatic data were extracted from tumors included in the latest version of the TP53 mutation database (<http://p53.fr>). For several studies, matched normal DNA was not available. dbSNP were extracted from version NCBI dbSNP Build 148 (<http://www.ncbi.nlm.nih.gov/snp>). For most variants described in dbSNP, the minor allele frequency is less than 0.001.

^cTP53 genomic variant descriptions according to chromosomal reference sequence NC_000017.10 of the GRCh37 (hg19) genome assembly.

^dRef-Seq transcript NM_000546.5 encodes the TP53 full-length protein (NP_000537.3).

^eTP53 coding DNA variant descriptions according to Ref-Seq transcripts encoding TP53β (NM_00126114.2).

^fTP53 coding DNA variant descriptions according to Ref-Seq transcripts encoding TP53γ (NM_00119586.1).

^gTP53 protein variant descriptions according to Ref-Seq proteins TP53β (NP_00119586.1).

^hTP53 protein variant descriptions according to Ref-Seq proteins TP53γ (NP_00119585.1).

ⁱBoth T-ALL cell lines carry the same rare variant, suggesting cross-contamination.

^jThis variant was described as germline in a patient with a pediatric neuroblastoma.

^kThe variant in this patient was shown to modify TP53 splicing.

Box B: Describing TP53 variants unambiguously

1. Use the official HGNC gene symbol: *TP53*
2. Specify the **genomic** reference sequence. For next-generation sequencing, use the chromosomal accession and version number NC_000017.10 for genome build GRCh37.p13 or NC_000017.11 for genome build GRCh38.p2. Do not replace by chr 17!

For diagnostic purposes, preferably use the stable Locus Reference Genomic sequence LRG_321 (http://ftp.ebi.ac.uk/pub/databases/lrgex/LRG_321.xml). See Dalglish and colleagues (<http://www.genomemedicine.com/content/pdf/gm145.pdf>; ref. 87) and Supplementary Fig. 2A and B.

3. Use HGVS nomenclature (<http://varnomen.hgvs.org/>) to describe genetic variants at all different levels

4. All variants **must** be reported at the genomic DNA (g.) and coding DNA level (c.). The genomic reference sequence **must** cover the entire gene, including the promoter and the 5' and 3' untranslated regions.

Example: genomic description LRG_321t1:g.18749G>A, coding DNA: LRG_321t1:c.818G>A

Alternative: the **accession and version number** of the corresponding RefSeq Gene NG_017013.2. Note: the annotation of this reference sequence may change without version update.

5. All variants **should** be reported at the RNA level (r.).

Example: LRG_321t1:r.818g>a (cDNA sequenced) or LRG_321t1:r.(818g>a) (cDNA not sequenced)

6. All variants **should** be reported using HGVS nomenclature at the protein level (p.)

Example: LRG_321p1:p.Arg273His (cDNA sequenced) or LRG_321p1:p.(Arg273His) (cDNA not sequenced)

7. **Predicted** effects at the RNA and protein level should be indicated in **parentheses**

8. A *dbSNP entry* (rs number) is insufficient to unambiguously describe the genetic variant found in an individual, because the alleles are not specified.

9. *Somatic variant*: Variant generated by a somatic *mutation event*. Variants should **only** be labeled as *somatic* when normal tissue from the same individual tested negative. When normal tissue from the same individual tested positive, the test has revealed a *germline variant*. When normal tissue from the same individual was unavailable and the variant has not been transmitted by one of the parents, the variant should be labeled as *detected in tumor (tissue)*.

names are more distinct and the numbers of amino acids in reference sequences is less than the number of nucleotides in the corresponding reference sequences. Due to the complexity of the human genome and the existence of genes with multiple transcripts and protein isoforms, description of the numerous variants associated with genetic diseases has become complicated and can lead to erroneous descriptions and growing confusion in the genetics community. For more than 15 years, the Human Genome Variation Society (HGVS) has provided guidelines for variant terminology and nomenclature (Box A to D; ref. 78). The consistent use of a uniform

Box C: Eliminating sources of confusion when reporting assay results in the literature

Specification of transcripts and protein isoforms.

TP53 transcripts should be specified using LRG_321 followed by the t1 to t8 suffixes (http://ftp.ebi.ac.uk/pub/databases/lrgex/LRG_321.xml). p53 protein isoforms should be specified using LRG_321 followed by the p1 to p13 suffixes. See Soussi and colleagues for examples (83).

Variants in the *TP53* gene may affect its 8 transcripts and 12 protein isoforms in different ways. Researchers should be aware of this variation when analyzing *TP53* functional effects using different assays at the RNA and protein level. If possible, the transcripts and protein isoforms analyzed by the assays should be specified when describing their results to avoid confusion. Validation of the ability of common p53 assays to detect various transcripts and protein isoforms could help to resolve existing discrepancies and seemingly contradictory data in the literature and databases.

nomenclature in the management of DNA sequence variations is critical for concise communication of diagnostic testing and genetic risk assessment. The importance of nomenclature has been recognized in the standards and guidelines for the interpretation of sequence variants recently published by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP; ref. 79). These guidelines are partly based on the HGVS guidelines for variant terminology (Box A) and take into account the fact that the meaning of certain terms may change as a result of changes in the contents of databases. The short genetic variation database,

Box D: *TP53* variants in human cancer: Unresolved questions

Which cancer types and/or subtypes will benefit the most from determination of *TP53* status?

To what degree does *TP53* loss of function induced by targeting certain upstream or downstream components, such as *MDM2* or *MDM4* amplification or microRNA dysregulation, resemble that induced by *TP53* variants?

What is the contribution of *TP53* variant heterogeneity to the phenotype of the tumor? (missense versus indel variants, hot spot versus non-hot spot variants)

What is the contribution of *TP53* isoforms to tumor phenotype?

What is the contribution of germline *TP53* mutations in familial cancer unrelated to LFS and LFL?

Is there any tumor or cell type specificity for loss and/or gain of function of *TP53* variants?

Which drugs would be the most effective on tumors with functional and nonfunctional p53 pathways?

What is the impact of synonymous variants in *TP53* and codon usage on p53 protein expression and function?

dbSNP, originally contained only high-frequency variants, but started to accept disease-causing variants and somatic variants with build 134 in 2011. Many researchers still regard dbSNP entries as variants with no functional effects, which has become a major source of confusion.

It is important to realize that genetic variants are mainly detected at the nucleotide level by DNA and RNA sequencing and should therefore be reported in terms of DNA and RNA sequences (Box B) to avoid the assumption that sequence variants do not alter gene expression or splicing. Reporting variants at a level other than where they were detected should be regarded as a form of interpretation. Variant descriptions in terms of protein and RNA (when RNA was not sequenced) should therefore reflect this fact by using parentheses flanking the description. Correct interpretation of variants and their effects as determined in functional assays is important for optimal patient care. It is currently unclear which transcripts and protein isoforms have been assessed by the various assays. The ability of assays to detect the different transcripts and protein isoforms must therefore be validated. After validation of the assay, the results of clinical and scientific reports should be accompanied by specification of the transcripts and protein isoforms potentially detected by the assay (Box C).

Conclusions

Accurate assessment of *TP53* status is essential for optimal patient care, but several major questions remain unresolved (Box D). The recent discovery of *TP53* variants within regions outside the sequences encoding the canonical form of the p53 protein calls for reconsideration of the guidelines for *TP53* mutation screening in cancer patients. The use of NGS readily allows increased coverage of *TP53* sequences with no significant increase in cost or analysis time. However, implementing *TP53* intronic and alternative exonic sequences in NGS depends on the selection of appropriate regions by probes deduced from databases derived from the Consensus Coding Sequence Project (CCDS) or other similar databases. Only the recent versions of these databases include full information on alternative *TP53* exons, but it remains unclear whether this information is taken into account by the manufacturers of the various commercial products used for exome sequencing. Moreover, many standard bioinformatic pipelines used for the identification of somatic variants are tailored to exclude intronic *TP53* variants because they were not thought to have any functional significance. Therefore, large-scale studies on the precise clinical significance of *TP53* variants in introns and alternative exons are now required to improve our understanding of the significance of these regions (Box D). In the meantime, a pragmatic recommendation would be to consider the entire sequence of the *TP53* gene for mutation screening strategies using NGS in sporadic cancers as well as in the germline of subjects who meet the criteria for *TP53* mutation testing (80–82).

Disclosure of Potential Conflicts of Interest

T. Zenz reports receiving speakers bureau honoraria from Gilead and is a consultant/advisory board member for Abbvie. No potential conflicts of interest were disclosed by the other authors.

Received August 8, 2016; revised November 12, 2016; accepted November 16, 2016; published OnlineFirst March 1, 2017.

References

- McDermott U, Downing JR, Stratton MR. Genomics and the continuum of cancer care. *N Engl J Med* 2011;364:340–50.
- Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. *Nature* 2013;502:333–9.
- Soussi T. Locus-specific databases in cancer: what future in a post-genomic era? The TP53 LSDB paradigm. *Hum Mutat* 2014;35:643–53.
- Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. *Nat Rev Cancer* 2014;14:455–67.
- Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. *Science* 1989;244:217–21.
- Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, et al. p53: a frequent target for genetic abnormalities in lung cancer. *Science* 1989;246:491–4.
- Soussi T, Ishioka C, Claustres M, Beroud C. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. *Nat Rev Cancer* 2006;6:83–90.
- Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. *Cold Spring Harb Perspect Biol* 2010;2:a001008.
- Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. *Hum Mutat* 2014;35:672–88.
- Nichols KE, Malkin D. Genotype versus phenotype: The Yin and Yang of Germline TP53 mutations in Li-Fraumeni Syndrome. *J Clin Oncol* 2015;33:2331–3.
- Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. *Oncogene* 2005;24:2899–908.
- Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. *Genes Dev* 2012;26:1268–86.
- Wang SJ, Gu W. To be, or not to be: functional dilemma of p53 metabolic regulation. *Curr Opin Oncol* 2014;26:78–85.
- Candi E, Agostini M, Melino G, Bernassola F. How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors. *Hum Mutat* 2014;35:702–14.
- Stündt MH, Müller PA, Ludwig RL, Kehrlöesser S, Dötsch V, Vousden KH. Functional interplay between MDM2, p63/p73 and mutant p53. *Oncogene* 2015;34:4300–10.
- Marine JC. MDM2 and MDMX in cancer and development. *Curr Top Dev Biol* 2011;94:45–75.
- Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. *Nature* 2009;458:1127–30.
- Hock AK, Vousden KH. Tumor suppression by p53: fall of the triumvirate? *Cell* 2012;149:1183–5.
- Lee P, Vousden KH, Cheung EC. TIGAR, TIGAR, burning bright. *Cancer Metab* 2014;2:1.
- Kruiswijk F, Labuschagne CF, Vousden KH. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. *Nat Rev Mol Cell Biol* 2015;16:393–405.
- Bieging KT, Attardi LD. Cancer: a piece of the p53 puzzle. *Nature* 2015;520:37–8.
- Soussi T, Wiman KG. TP53: an oncogene in disguise. *Cell Death Differ* 2015;22:1239–49.
- Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, et al. MDM4 is a key therapeutic target in cutaneous melanoma. *Nat Med* 2012;18:1239–47.
- Eischen CM, Lozano G. The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. *Hum Mutat* 2014;35:728–37.
- Qi J, Singh S, Hua WK, Cai Q, Chao SW, Li L, et al. HDAC8 inhibition specifically targets Inv(16) acute myeloid leukemic stem cells by restoring p53 acetylation. *Cell Stem Cell* 2015;17:597–610.
- Cooper GM. Parlez-vous VUS. *Genome Res* 2015;25:1423–6.
- Amendola LM, Dorschner MO, Robertson PD, Salama JS, Hart R, Shirts BH, et al. Actionable exomic incidental findings in 6503 participants: challenges of variant classification. *Genome Res* 2015;25:305–15.
- Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. *Hum Mutat* 2007;28:622–9.
- Carlsson J, Soussi T, Persson B. Investigation and prediction of the severity of p53 mutants using parameters from structural calculations. *FEBS J* 2009;276:4142–55.
- Osman AA, Neskey DM, Katsonis P, Patel AA, Ward AM, Hsu TK, et al. Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients. *Cancer Res* 2015;75:1205–15.
- Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. *Nat Rev Cancer* 2014;14:359–70.
- Oren M, Rotter V. Mutant p53 gain-of-function in cancer. *Cold Spring Harb Perspect Biol* 2010;2:a001107.
- Jackson JG, Lozano G. The mutant p53 mouse as a pre-clinical model. *Oncogene* 2013;32:4325–30.
- Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. *Cell* 2004;119:847–60.
- Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. *Cell* 2004;119:861–72.
- Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G. Mutant p53: an oncogenic transcription factor. *Oncogene* 2007;26:2212–9.
- Silwal-Pandit L, Vollen HK, Chin SF, Rueda OM, McKinney S, Osako T, et al. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. *Clin Cancer Res* 2014;20:3569–80.
- Robles AI, Harris CC. Clinical outcomes and correlates of TP53 mutations and cancer. *Cold Spring Harb Perspect Biol* 2010;2:a001016.
- Petitjean A, Achatz MJ, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. *Oncogene* 2007;26:2157–65.
- Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, et al. p53 in breast cancer subtypes and new insights into response to chemotherapy. *Breast* 2013;22Suppl 2:S27–9.
- Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. *Clin Cancer Res* 2006;12:1157–67.
- Young KH, Leroy K, Moller MB, Colleoni GW, Sanchez-Beato M, Kerbaux FR, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. *Blood* 2008;112:3088–98.
- Gruber M, Wu CJ. Evolving understanding of the CLL genome. *Semin Hematol* 2014;51:177–87.
- Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. *Blood* 2014;123:3247–54.
- Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. *Leukemia* 2012;26:1458–61.
- Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. *Nat Rev Clin Oncol* 2013;10:472–84.
- Izumchenko E, Chang X, Brait M, Fertig E, Kagohara LT, Bedi A, et al. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. *Nat Commun* 2015;6:8258.
- Betgeowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med* 2014;6:224ra24.
- Müller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. *Cancer Cell* 2014;25:304–17.
- Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. Restoration of p53 function leads to tumour regression in vivo. *Nature* 2007;445:661–5.
- Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. *Cell* 2006;127:1323–34.
- Lehmann S, Bykov VJ, Ali D, Andren O, Cherif H, Tidfelt U, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246

- in refractory hematologic malignancies and prostate cancer. *J Clin Oncol* 2012;30:3633–9.
53. Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, et al. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. *Nature* 2015;523:352–6.
 54. Zhang S, Zhou L, Hong B, van den Heuvel AP, Prabhu VV, Warfel NA, et al. Small-molecule NSC59984 restores p53 pathway signaling and antitumor effects against colorectal cancer via p73 activation and degradation of mutant p53. *Cancer Res* 2015;75:3842–52.
 55. Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. *Nat Rev Clin Oncol* 2011;8:25–37.
 56. Malkin D, Li FP, Strong LC, Fraumeni JFJ, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science* 1990;250:1233–8.
 57. McBride KA, Ballinger ML, Killick E, Kirk J, Tattersall MH, Eeles RA, et al. Li-Fraumeni syndrome: cancer risk assessment and clinical management. *Nat Rev Clin Oncol* 2014;11:260–71.
 58. Gonzalez KD, Buzin CH, Noltner KA, Gu D, Li W, Malkin D, et al. High frequency of de novo mutations in Li-Fraumeni syndrome. *J Med Genet* 2009;46:689–93.
 59. Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. *Lancet Oncol* 2011;12:559–67.
 60. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. *Proc Natl Acad Sci U S A* 2001;98:9330–5.
 61. Legal EF, Ascurra M, Custódio G, Ayala HL, Monteiro M, Vega C, et al. Prevalence of an inherited cancer predisposition syndrome associated with the germ line TP53 R337H mutation in Paraguay. *Cancer Epidemiol* 2015;39:166–9.
 62. Giacomazzi J, Selistre SG, Rossi C, Alemar B, Santos-Silva P, Pereira FS, et al. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil. *Cancer* 2013;119:4341–9.
 63. McCuaig JM, Armel SR, Novokmet A, Ginsburg OM, Demsky R, Narod SA, et al. Routine TP53 testing for breast cancer under age 30: ready for prime time? *Fam Cancer* 2012;11:607–13.
 64. Maxwell KN, Wubbenhorst B, D'Andrea K, Garman B, Long JM, Powers J, et al. Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. *Genet Med* 2015;17:630–8.
 65. Li J, Meeks H, Feng BJ, Healey S, Thorne H, Makunin I, et al. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families. *J Med Genet* 2016;53:34–42.
 66. Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. *Cancer* 2015;121:25–33.
 67. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. *Nature* 1989;342:705–8.
 68. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, et al. p53 isoforms can regulate p53 transcriptional activity. *Genes Dev* 2005;19:2122–37.
 69. Marcel V, Dichtel-Danjoy ML, Sagne C, Hafsi H, Ma D, Ortiz-Cuaran S, et al. Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. *Cell Death Differ* 2011;18:1815–24.
 70. Slatter TL, Hung N, Campbell H, Rubio C, Mehta R, Renshaw P, et al. Hyperproliferation, cancer, and inflammation in mice expressing a $\Delta 133$ p53-like isoform. *Blood* 2011;117:5166–77.
 71. Flaman JM, Waridel F, Estreicher A, Vannier A, Limacher JM, Gilbert D, et al. The human tumour suppressor gene p53 is alternatively spliced in normal cells. *Oncogene* 1996;12:813–8.
 72. Surget S, Khoury MP, Bourdon JCS-PL. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. *Onco Targets Ther* 2013;7:57–68.
 73. Masuda H, Miller C, Koeffler HP, Battifora H, Cline MJ. Rearrangement of the p53 gene in human osteogenic sarcomas. *Proc Natl Acad Sci U S A* 1987;84:7716–9.
 74. Miller CW, Aslo A, Tsay C, Slamon D, Ishizaki K, Toguchida J, et al. Frequency and structure of p53 rearrangements in human osteosarcoma. *Cancer Res* 1990;50:7950–4.
 75. Ribí S, Baumhoer D, Lee K, Edison, Teo AS, Madan B, et al. TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome. *Oncotarget* 2015;6:7727–40.
 76. Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. *Cell Rep* 2014;7:104–12.
 77. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. *Nature* 1992;358:80–3.
 78. den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. *Hum Mutat* 2000;15:7–12.
 79. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015;17:405–24.
 80. Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, et al. 2009 version of the Chompret criteria for Li-Fraumeni syndrome. *J Clin Oncol* 2009;27:e108–9; author reply e110.
 81. Hettmer S, Archer NM, Somers GR, Novokmet A, Wagers AJ, Diller L, et al. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. *Cancer* 2014;120:1068–75.
 82. Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. *J Clin Oncol* 2015;33:2345–52.
 83. Soussi T, Leroy B, Taschner PE. Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era. *Hum Mutat* 2014;35:766–78.
 84. Kern SE, Winter JM. Elegance, silence and nonsense in the mutations literature for solid tumors. *Cancer Biol Ther* 2006;5:349–59.
 85. Stacey SN, Sulem P, Jonasdottir A, Masson G, Gudmundsson J, Gudbjartsson DF, et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. *Nat Genet* 2011;43:1098–103.
 86. Iggo R, Rudewicz J, Monceau E, Sevenet N, Bergh J, Sjoblom T, et al. Validation of a yeast functional assay for p53 mutations using clonal sequencing. *J Pathol* 2013;231:441–8.
 87. Dalgleish R, Flicek P, Cunningham F, Astashyn A, Tully RE, Proctor G, et al. Locus reference genomic sequences: an improved basis for describing human DNA variants. *Genome Med* 2010;2:24.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Recommended Guidelines for Validation, Quality Control, and Reporting of *TP53* Variants in Clinical Practice

Bernard Leroy, Mandy L. Ballinger, Fanny Baran-Marszak, et al.

Cancer Res Published OnlineFirst March 2, 2017.

Updated version Access the most recent version of this article at:
doi:[10.1158/0008-5472.CAN-16-2179](https://doi.org/10.1158/0008-5472.CAN-16-2179)

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.